Effect of Sodium Valproate Treatment on the Cardiac Index in New Cases with Status Epilepticus Alternate Title: Effect of Sodium Valproate Treatment on the Cardiac Index



Mohammad Radgoudarzi1, Mohammad Vafaee-Shahi2, *, Fatemeh Naderi1
1 Department of Pediatric Cardiology, Hazrat Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
2 Department of Pediatric Neurology, Pediatric growth and development research center, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background:

Sodium valproate is an antiepileptic drug primarily used to treat status epilepticus [SE]; however, its effect on cardiac function is unclear. This study aimed to examine the effect of 6 months of sodium valproate treatment on the cardiac index in new cases with status epilepticus.

Methods:

In this cross-sectional study, 30 cases with status epilepticus [18 boys and 12 girls] who were admitted to the Pediatric Intensive Care Unit of Hazrat-e Rasool Hospital were enrolled. Information on basic demographic and clinical data of all children, such as age, weight, gender, blood pressures, and underlying diseases, was recorded. Echocardiography and electrocardiogram [ECG] were performed for all cases before and after the treatment.

Results:

There were no abnormalities in ECG parameters [including PR, QRS, and QT intervals] after 6 months of treatment with sodium valproate. No significant differences were found in echocardiographic parameters, including blood pressure, pulmonary artery pressure [PAP], right ventricular [RV] size, diastolic dysfunction,], Tie index, end-diastolic volume [EDV], ejection fraction [EF], and TAPSE before and after study [p>0.05].

Conclusion:

Administration of sodium valproate over 6 months is not associated with a serious adverse effect on heart function in children with status epilepticus.

Keywords: Status epilepticus, Cardiac function, Children, Sodium valproate, Seizure, Valproic acid.


Abstract Information


Identifiers and Pagination:

Year: 2022
Volume: 16
Publisher Item Identifier: EA-TONEUJ-2021-12

Article History:

Electronic publication date: 18/2/2022
Collection year: 2022

© 2022 Radgoudarzi et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


* Address correspondence to this author at the Pediatric growth and development research center, institute of Endocrinology and metabolism, Iran University of Medical Sciences, Tehran, Iran; Tel: +989133514636, + 982166525328; Fax: 982166525328; E-mails: dr.vafaeeshahi@gmail.com, vafaeeshahi.m@iums.ac.ir